Eyebrow Lift (Chemical Brow Lift) Anti-Wrinkle Injection Policy

Published:

November 4, 2025

1. Purpose

Provide a safe, evidence-based framework for non-surgical eyebrow elevation using botulinum toxin type A (BoNT-A), aligned with Australian cosmetic-medicine governance and international safety standards. ¹

2. Scope

Applies to AHPRA-registered practitioners performing or supervising anti-wrinkle injections targeting the frontalis, corrugator, and lateral orbicularis oculi muscles for conservative brow elevation. ¹

3. Governance (Australia)

Requires a face-to-face prescriber consultation, adherence to TGA restrictions on advertising Schedule 4 medicines, and clinical documentation under NSQHS medication-safety standards. ¹

4. Anatomy & Injection Mapping

The chemical brow lift relies on weakening depressor muscles (corrugator, procerus, and lateral orbicularis oculi) while maintaining frontalis elevator tone. Consensus technique: inject 1–2 U per site into lateral canthal and glabellar depressor zones, keeping injections ≥ 1 cm above the orbital rim. ⁴

5. Dosing (Guideline Based)

Typical total dose ≈ 6–10 U per side, adjusted to facial strength and symmetry. Follow manufacturer-independent clinical guidance for glabellar + periorbital dosing as per international consensus and Australian regulatory standards. ⁵

6. Contraindications

Defer in pregnancy, breastfeeding, local skin infection, or neuromuscular disorders. Review medical and allergy history prior to treatment. ²

7. Informed Consent & Risks

Explain realistic outcomes (mild lateral lift ≈ 2–3 mm), risk of eyelid heaviness or ptosis, bruising, or asymmetry, and that effects are temporary (~3–4 months). ¹

8. Post-Treatment Care

Remain upright ≥ 4 h, avoid pressure, exercise, and heat exposure for 24–48 h; re-evaluate symmetry at 2 weeks. ²

9. Adverse Events & Management

Eyelid ptosis may respond to apraclonidine 0.5 % drops; document and follow-up. Bruising is self-limiting; advise gentle care. ⁶

10. Documentation & Audit

Record prescriber, injector, product, batch, expiry, dose, injection map, consent, and review outcomes. Maintain annual audits and ≥ 20 hours CPD in cosmetic injectables. ³

Sources

AHPRA 2025, Guidelines for Cosmetic Medical and Surgical Procedures, Canberra., viewed 04 November 2025, https://www.ahpra.gov.au/News/2025-09-02-New-guidelines-for-cosmetic-procedures.aspx ↩
Queensland Health 2024, Beginner’s Guide to Cosmetic Injectables, Brisbane., viewed 04 November 2025, https://www.health.qld.gov.au/newsroom/news/beginner-friendly-guide-to-cosmetic-injectables ↩
Australian Commission on Safety and Quality in Health Care (ACSQHC) 2023, NSQHS Standards – Medication Safety, Sydney., viewed 04 November 2025, https://www.safetyandquality.gov.au ↩
American Society for Dermatologic Surgery (ASDS) 2022, Resident Training Guide: Dose, Dilution and Injection Technique for Botulinum Toxin Type A in Cosmetic Practice, ASDS Education Series., viewed 04 November 2025, https://www.asds.net/Portals/0/PDF/Resident-Kit-Allergan-BOTOX-Cosmetic-Dosing-Reconstitution-Tool.pdf ↩
AbbVie Medical Information 2024, Highlights of Prescribing Information – Botulinum Toxin Type A for Cosmetic Use (Glabellar and Periorbital Lines), US Label Reference., viewed 04 November 2025, https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf ↩
Nestor MS, Ablon GR, Newburger J et al. 2021, Botulinum Toxin–Induced Blepharoptosis: Anatomy, Etiology, and Management, Journal of Cosmetic Dermatology, 20(8):2314–2322., viewed 04 November 2025, https://onlinelibrary.wiley.com/doi/10.1111/jocd.14361 ↩

Disclaimer for Newcastle Cosmetic Doctor Policies & Procedures

The policies and procedures contained within this document are the exclusive property of Newcastle Cosmetic Doctor and are provided for internal clinical governance and educational purposes only. These materials represent the internal operational framework, safety standards, and evidence-based protocols developed and implemented by Dr. Bart John Scanlon and the Newcastle Cosmetic Doctor team. They are designed specifically for use within Newcastle Cosmetic Doctor and reflect our clinic’s own professional standards, risk assessments, and compliance obligations under Australian law and regulatory authorities. External individuals, practitioners, or organisations must not copy, reproduce, distribute, or rely upon these materials, in whole or in part, for their own clinical, commercial, or educational use without prior written consent from Newcastle Cosmetic Doctor. These materials do not constitute medical, legal, or professional advice and are not intended to be adopted as official protocols or procedures by any other entity. Any external use or adaptation must be independently reviewed and modified to meet the relevant laws, guidelines, and standards applicable to the user’s own jurisdiction, scope of practice, and facility operations. Newcastle Cosmetic Doctor and Dr. Bart Scanlon accept no liability for any loss, injury, or damage arising from the unauthorised use, reliance upon, or misinterpretation of this material.